Research Analysts Set Expectations for BCRX Q4 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – HC Wainwright lifted their Q4 2024 EPS estimates for shares of BioCryst Pharmaceuticals in a report released on Tuesday, November 5th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn ($0.01) per share for the quarter, up from their previous forecast of ($0.03). HC Wainwright currently has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.49 EPS, FY2027 earnings at $0.91 EPS and FY2028 earnings at $1.31 EPS.

Several other equities research analysts have also recently weighed in on BCRX. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $7.67 on Thursday. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -12.57 and a beta of 1.89. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The business’s 50 day simple moving average is $7.78 and its 200-day simple moving average is $6.98.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same period in the previous year, the company posted ($0.19) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% on a year-over-year basis.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in BCRX. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 13.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 138,074 shares of the biotechnology company’s stock worth $701,000 after purchasing an additional 15,894 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $327,000. Inspire Investing LLC boosted its holdings in BioCryst Pharmaceuticals by 9.7% during the 1st quarter. Inspire Investing LLC now owns 69,466 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 6,141 shares during the period. Russell Investments Group Ltd. boosted its holdings in BioCryst Pharmaceuticals by 200.8% during the 1st quarter. Russell Investments Group Ltd. now owns 58,725 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 39,205 shares during the period. Finally, ProShare Advisors LLC grew its position in BioCryst Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 4,041 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.